Abstract High circulating glucose has been associated with increased risk of breast cancer (BC). There may also be a link between serum glucose and prognosis in women treated for BC. We assessed the effect of peridiagnostic fasting blood glucose and body mass index (BMI) on longterm BC prognosis. We retrospectively investigated 1,261 women diagnosed and treated for stage I-III BC at the National Cancer Institute, Milan, in 1996Milan, in , 1999Milan, in and 2000. Data on blood tests and follow-up were obtained by linking electronic archives, with follow-up to end of 2009. Multivariate Cox modelling estimated hazard ratios (HR) with 95 % confidence intervals (CI) for distant metastasis, recurrence and death (all causes) in relation to categorized peridiagnostic fasting blood glucose and BMI. Mediation analysis investigated whether blood glucose mediated the BMI-breast cancer prognosis association. The risks of distant metastasis were significantly higher for all other quintiles compared to the lowest glucose quintile (reference\87 mg/dL) (respective HRs: 1.99 95 % CI 1.23-3.24, 1.85 95 % CI 1.14-3.0, 1.73 95 % CI 1.07-2.8, and 1.91 95 % CI 1.15-3.17). The risk of recurrence was significantly higher for all other glucose quintiles compared to the first. The risk of death was significantly higher than reference in the second, fourth and fifth quintiles. Women with BMI C 25 kg/m 2 had significantly greater risks of recurrence and distant metastasis than those with BMI \ 25 kg/m 2 , irrespective of blood glucose. The increased risks remained invariant over a median follow-up of 9.5 years. Mediation analysis indicated that glucose and BMI had independent effects on BC prognosis. Peridiagnostic high fasting glucose and obesity predict worsened short-and long-term outcomes in BC patients. Maintaining healthy blood glucose levels and normal weight may improve prognosis.
Introduction
Breast cancer (BC) is the commonest cancer in women. A role of high circulating glucose in carcinogenesis was first suggested by Warburg in the 1920s [1] . In 1962 it was reported that two psychotic patients, who were given insulin (with induction of hypoglycaemic coma) experienced complete remission of metastatic BC [2] . In 1977 Carroll reported an ecological correlation between procapita sugar intake and BC mortality [3] . In 2002, the prospective ORDET study found that high fasting glucose was a risk factor for BC, further supported by a second ORDET study with longer follow-up [4, 5] .
By contrast Holmes et al. [6] found no association between glycaemic index or glycaemic load, and BC risk. A study on the Swedish National Diabetes Register cohort also found no relation between diabetes and cancer [7] .
The original observation of Warburg, that high glucose favours the selection of malignant cell clones resistant to hypoxia, in which energy is produced mainly by glycolysis, is one biological mechanism linking cancer development with high circulating glucose [8, 9] . Enhanced glycolysis and glucose uptake characterizes most tumour cells [1] . Glucose metabolism may also promote malignant change through the generation of free radicals that damage both DNA and the enzymes involved in DNA repair and processing [10, 11] . It has also been found that levels of glucose transporters are elevated in most human cancers, including BC [12, 13] .
As regards BC prognosis, evidence of a link to circulating glucose levels is more limited. A study on cultured BC cells found reduced chemotherapy-induced cell death in cells subjected to high glucose concentrations, suggesting that hyperglycaemia confers resistance to chemotherapy [14] . A dietary intervention study in BC patients found that the risk of recurrence was significantly higher in patients with metabolic syndrome-one of whose main characteristics is elevated blood glucose [15] .The HEAL cohort study also provided some indication that dietary glycaemic load might be related to BC prognosis [16] , while an observational study on 46 cancer patients, eight with BC, found significantly lower average blood glucose in patients in remission [17] . Finally, a recent cohort study on non-diabetic BC patients found an association between blood glucose and distant metastasis but only for the first 5 years after diagnosis [18] .
The aim of the present study was to investigate the relationship between long-term BC prognosis and fasting glucose levels by retrospectively examining two large consecutive series of BC patients. Furthermore, since high blood glucose is often associated with overweight, we also investigated whether glucose and body mass index (BMI) had independent or related effects on prognosis, and whether blood glucose mediates the association between BMI and prognosis. We evaluated the effects of these variables on any BC recurrence, distant metastasis, and death for any cause.
Methods

Patients
We retrospectively examined two consecutive series of BC patients treated at the National Cancer Institute of Milan (NCIM) in 1996 and 1999-2000, adhering to the following criteria: resident in the Region of Lombardy at moment of diagnosis, no previous cancer diagnosis (except non-melanoma skin cancer), fasting blood glucose determined peridiagnostically (and available) and stage I-III BC (T1-T3,  N0-N1, M0) . We conducted a pilot investigation of cases from 1999 to 2000 and subsequently added 1996 cases to increase cohort size and lengthen median follow-up.
Cases were initially identified automatically from the prospectively maintained electronic database of NCIM case records (Step 1a, Fig. 1 ). We next used the Epilink software to perform statistically based linkage of NCIM cases to hospital discharge files for the entire Region of Lombardy [19] . This process also involved linkage to Region of Lombardy Social Security filesto verify Region of Lombardy residency. The outcome of this procedure was that incident cases (Step 2, Fig. 1 ) were separated from prevalent cases which were eliminated.
In a separate procedure (Step 1b, Fig. 1 ), we applied Epilink to cases archived in the NCIM analytical laboratory database, selecting female patients with fasting glucose determinations.
To identify BC cases (incident at NCIM in the study years) that also had peridiagnostic fasting glucose we manually checked the few records (1 %) flagged by Epilink in Steps 1a and 1b as having uncertain linkage, and linked cases from Step 1b with those from Step 2.
The next step (Step 3, Fig. 1 ) was hand-searching the clinical records of identified cases. This served as an additional check that case details were correct, and provided the following additional information: BMI (kg/m 2 ), disease stage (TNM), menopausal status at diagnosis, and tumour oestrogen and progesterone receptor data. A series of algorithms included in the Open Registry software [20] was then applied to ascertain whether any adverse BC events for these cases had been registered in the hospital discharge database of the Region of Lombardy from 1996 to 2009. Cases with an adverse event were then handsearched in clinical records (Step 4, Fig. 1 ) to confirm the event and obtain details (locoregional recurrence, distant metastasis, death). Finally (Step 5, Fig. 1 ), the vital status of all cases was checked on Social Security files up to 31/12/2009 (end of follow-up). Thirty-one (2.5 %) women were identified as having moved out of the Region of Lombardy before the close of follow-up and were considered lost to follow-up at the date of moving.
Statistical methods
Associations between glucose and other patient variables were analysed by Chi square test, with glucose categorized into quintiles, and age, menopausal status, tumour stage, BMI and oestrogen and progesterone receptor status, categorized as in Table 1 . Spearman rank correlation coefficients were determined to examine correlations between selected variables.
Step Step 4: consultation of clinical records of Lombardy hospitals to identify disease recurrences
Step 5: linkage with Social Security files 317 deaths The study had three end-points: any BC recurrence, distant metastasis and all-cause mortality. Some women contributed to all three endpoints. The Kaplan-Meier method was used to visualize the effects of variables on endpoints. Cox proportional hazard modelling was used to estimate hazard ratios (HRs) with 95 % confidence intervals (CI) for any recurrence, distant metastasis and allcause death by quintiles of fasting blood glucose (lowest as reference), also by dichotomized BMI (\25 vs. C25 kg/m 2 , lower as reference), adjusting by age (five-year classes), menopausal status (according to Table 1 categories), oestrogen and progesterone receptor status (positive or negative) and tumour stage. Postmenopausal status was defined as absence of menstruation for at least 12 months. Time to an event or end of follow-up was calculated from date of diagnosis. The proportional hazards assumption was tested by analysis of scaled Schoenfeld residuals, with P values for each variable estimated. When the hazard for a variable was suspected to be non-proportional over time, we performed additional analyses, substituting the conventional Cox model b coefficient (for a given variable) with a time-dependent function b(t) obtained by adding the smoothed scaled Schoenfeld residuals to the conventional b coefficient [21] . The results were evaluated as suggested by Grambsch et al. [19] and Bellera et al. [22] . When nonproportional hazards were found for covariates other than glucose and BMI, we stratified the Cox models by these covariates.
We ran semi-adjusted models that included all covariates except glucose (when assessing BMI) and BMI (when assessing glucose), and fully-adjusted models that included all covariates (including glucose and BMI). The methodology of MacKinnon et al. [23] was employed to test whether blood glucose mediates the causal relationship (5) 18 (8) 28 (11) 36 (13) 51 (21) 146 Unknown 51 (20) 49 (21) 38 (16) 48 (17) 62 (25) between BMI and BC prognosis. To be considered a mediator of this relationship, blood glucose: (a) must be correlated with BMI; (b) must remain associated with prognosis after adjusting for BMI; (c) must partially or totally explain the effect of BMI on prognosis.
(a) was assessed by correlation analysis and (b) by Cox proportional hazards analysis. To ascertain (c) we calculated b for BMI in the semi-adjusted model without blood glucose, then ran the fully-adjusted model adding blood glucose into the analysis and obtaining a new coefficient (b 0 ) for BMI. We then tested the b-b 0 difference by the Freedman and Scatzkin test [24] . The percentage attenuation of s following the introduction of blood glucose introduction was calculated as ððb À Àb0Þ=bÞ Ã 100. The analyses were performed using the R statistical package [25] .
Results
Cohort
A total of 12,028 women in the NCIM hospital discharge database, years 1996, 1999 and 2000, had a diagnosis of BC. By linkage with Social Security files 5509 of these had a Region of Lombardy residence code. By linkage of these cases with Lombardy hospital discharge files for years before the study period, 3,651 women were excluded as prevalent cases or as having a diagnosis of another cancer, and 1,858 cases were identified as incident BCs. In a separate process, records of blood glucose tests performed by the NCIM analytical laboratory, in the years of the study, were linked with Social Security files, from which 18,393 records were identified as belonging to female residents in the Region of Lombardy. By linkage of these cases with the 1,858 incident BC cases, 1,759 BCs cases with peridiagnostic glucose levels were identified, and 99 were excluded. Hand-searching of the clinical records of these cases led to the exclusion of a further 498 cases of prevalent (N = 195), stage unknown (N = 142), noninvasive (N = 95), or metastatic (N = 66) BC at diagnosis. We conducted the analysis on 1,261 cases, fully respecting the predefined study criteria.
The clinical characteristics of these cases are shown in Table 1 . During a median follow-up of 9.5 years (maximum 13.5 years), 107 locoregional recurrences, 293 distant metastases and 317 deaths were identified (more than one event possible in any woman). Two-thirds (65.2 %) of the women were postmenopausal. Mean age was 57 years. Mean fasting glucose was 100.6 mg/dL (range 68-401). Women with high glucose were more likely to be older, more often menopausal, have higher BMI, and more advanced disease stage at diagnosis.
Disease progression and fasting glucose
Preliminary analyses identified non-proportional hazards in relation to oestrogen receptor status, progesterone receptor status, disease stage, and age, so the final models were stratified for these variables.
In the semi-adjusted model (without BMI), HRs for distant metastasis were significantly above reference (lowest quintile) for women in the other four quintiles of the glucose distribution (Table 2 ). In the fully-adjusted model (with BMI), HRs were slightly lower but always significantly greater than reference.
Risk of any BC recurrence was also significantly above reference for women in the other four glucose quintiles in the semi-adjusted model, but were attenuated in the fullyadjusted model, when they were no longer significant for the third and fourth quintiles.
The risk of all-cause death was significantly above reference for women in the second, fourth and fifth glucose quintiles in the fully-adjusted model (Table 2) .
High glucose was associated with increased risk of distant metastasis in both categories of BMI. To further probe the relationship between fasting glucose and prognosis we repeated the analyses with the covariate BMI categorized as recommended by the WHO (\18.5; C18.5 \ 25; C25 \ 30; C30 kg/m 2 ) and also considering BMI as a continuous variable. The results (not shown in Tables) were closely similar to those shown in  Tables 2 and 3 . For example the HR for distant metastasis in the highest glucose quintile was 1.72 compared to reference, while with BMI as continuous variable the corresponding HR was 1.74 (c.f. HR 1.91 in Table 2 ).
Disease progression and BMI
Compared to reference (\25 kg/m 2 ) women with BMI C 25 kg/m 2 had significantly greater risks of any recurrence and distant metastasis, but not death (Table 3 ). In the semi-adjusted model (excluding glucose) the HR for distant metastasis was 1.57 (95 % CI 1.17-2.10) in the higher BMI category, and remained significant in the fullyadjusted model. Risk of any recurrence was also significantly influenced by BMI both in the semi-and fullyadjusted models, but BMI had only a minor effect on all-cause mortality (Table 3 ).
Prognostic effects of high glucose and high BMI over time Analyses of scaled Schoenfeld residuals showed that the proportional hazard assumption held for glucose over time. Specifically, for distant metastasis as outcome, P values for increasing glucose quintiles compared to the lowest were 0.11, 0.47, 0.42 and 0.06, indicating that the null hypothesis of no variation of hazard with time could not be rejected, and suggesting that the prognostic effect of glucose remained constant over the entire follow-up period. A similar result (P = 0.48) was obtained for the upper BMI category compared to reference. Hazard proportionality was also investigated for all recurrences and mortality, and found to hold for glucose and BMI (data not shown), implying that the prognostic effect of glucose and BMI on these endpoints remained constant over the entire follow-up.
Mediation analysis of relationship between fasting glucose and BMI
Fasting glucose and BMI correlated with each other (Spearman's r = 0.28, P = 0.002), hence, satisfying the first MacKinnon et al. [23] criterion. Fasting glucose also remained associated with prognosis after the introduction of the BMI into the statistical model as shown above (criterion b). We next applied MacKinnon [23] criterion (c) to determine whether blood glucose partially or totally explained the effect of BMI on prognosis. With distant metastasis as outcome the attenuation percentage was 13 %, and Freedman-Schatzkin test P value was 0.46, so the null hypothesis that blood glucose did not mediate the effect of BMI on distant metastasis could not be rejected. With any recurrence as outcome, attenuation percentage was 13.8 %, Freedman-Schatzkin test P value 0.53, so again the null hypothesis that blood glucose did not Table 2 Hazard ratios (HR) with 95 % CIs, for disease recurrence, distant metastasis and death, according to quintiles of peridiagnostic fasting blood glucose Models adjusted for menopausal status and stratified by oestrogen receptor status, progesterone receptor status, disease stage, and age. Semi-adjusted models exclude BMI, fully-adjusted models include BMI mediate the effect of BMI any recurrence could not be rejected. Finally, BMI was not significantly associated with death either before or after the introduction blood glucose into the statistical model, so again the null hypothesis (that blood glucose did not mediate the effect of BMI on death recurrence) was not rejected. We also did mediation analysis with BMI categorized into four levels, and as a continuous variable: in all cases results indicated that the null hypothesis of no mediation.
Discussion
The principal finding of this retrospective study on 1,261 women with invasive BC is that risks of any recurrence and of distant metastasis were significantly higher for those with fasting blood glucose in the four high quintiles of the distribution, compared to those in the lowest quintile (\87 mg/dL). Risk of death for any cause showed a similarly significant pattern. These risks were attenuated, but still usually significant, in the fully-adjusted model that included BMI (Table 2 ); while models run for high and low BMI separately estimated similarly increased risks for all quintiles of glucose above reference, although these were not significant in most cases, probably due to the considerably lower numbers of cases in each category. We also found that BMI was related to BC prognosis: the risks of BC recurrence and distant metastasis were significantly higher in overweight plus obese women (BMI C 25 kg/m 2 ) than normal weight plus underweight women (BMI \ 25 kg/m 2 ). These risks were slightly attenuated in the fully-adjusted model (with glucose as covariate). BMI was not significantly associated with allcause death.
Importantly, our analysis also indicated that the worsened prognosis of women with high glucose and high BMI remained constant over the entire follow-up.
The recent study of Goodwin et al. investigated insulinrelated (including fasting glucose) and obesity-related variables in 535 non-diabetic women treated for T1-3 N0-1 M0 BC [18] . They found that insulin-related variables (including glucose) were significantly associated with distant metastasis only for the first 5 years of follow-up; by contrast our study suggests that the increased risk persists over the long-term. In both studies the risks associated with BMI remained constant over time. Unlike the present study, Goodwin et al. found no significant association of fasting glucose with overall mortality.
The Diana-2 study investigated the relation of metabolic syndrome and its components to BC prognosis [15] . Metabolic syndrome at baseline was associated with an adjusted HR for recurrence of 3.0 (95 % CI 1.2-7.1) relative to no metabolic syndrome. High blood glucose (component of metabolic syndrome) was also associated with increased HRs for recurrence, but the association was not significant, probably in relation to the small numbers of both patients (N = 110) and adverse events (N = 31). The HEAL study investigated relations of dietary fibre, glycaemic index, and glycaemic load to adverse events in 688 BC patients followed for 6.7 years [16] . There was some indication that high glycaemic index was related to increased BC mortality and recurrences, but risk increases were not significant. Dietary glycaemic index and dietary glycaemic load may not correlate closely with fasting blood glucose.
With regard to the influence of obesity on BC prognosis, this has been investigated by several studies [26] [27] [28] . Ewertz et al. [26] 2 ) were associated with significantly greater risk of distant metastases after adjusting the models for disease characteristics.
A retrospective analysis of 2,887 lymph node-positive BC patients enrolled in the BIG 02-98 study [27] also found that baseline obesity was associated with significantly poorer outcomes. A meta-analysis of 43 studies, published in 2008, found an HR for breast cancer-specific mortality of 1.33 (95 % CI 1.19-1.50) in obese patients compared to non-obese patients [28] .
The findings of the present study on the prognostic effect of fasting glucose are, therefore, consistent with the results of previous studies and are reinforced by plausible biological mechanisms for effects of glucose on BC [1-5, 8, 9, 12, 13] .
Our study is the first to use statistical methods investigate whether fasting glucose levels mediated the association between BMI and BC prognosis. Our extensive analyses indicated that fasting glucose did not mediate this relationship, indicating that glucose and BMI have independent effects on BC prognosis.
A limitation of our study is that fasting glucose was only measured once. It would be useful to assess blood glucose at several time points during follow-up in the expectation that women with chronically high glucose would be at even greater risk of adverse events, and that those who correct hyperglycaemia and overweight have lowered risks.
Other limitation are the lack of information on comorbidities and biological factors like tumour proliferation rate and human epidermal growth factor receptor 2 overexpression, both of which are known to influence BC prognosis, and lack of information about the use of diabetic medications to lower blood sugar levels medications.
It is noteworthy that 85 % of our cohort had fasting serum glucose in the four highest quintiles, or BMI C 25 kg/m 2 , or both. Thus, a large vast majority of the patients in our cohort were at high risk of recurrence.
Conclusions
At the very least our data indicate that studies are necessary to determine whether long-term control of hyperglycaemia and reduction of obesity improves BC outcomes. Rapid and profound changes in eating habits are occurring in many countries, particularly those in South Asia, Africa, Latin America and China, that have been linked to increased incidence of obesity and chronic diseases [29] [30] [31] [32] . Thus, in Brazil more sugar is consumed than recommended by the WHO, and added sugars from processed foods and manufactured beverages form an increasing proportion of sugar intake [33] . The World Health Organization estimates that by 2015 over 2.3 billion people will be overweight, and that deaths due to diabetes will have increased by more than 50 % [34] . These projections suggest we are likely to see increase in the proportion of BC patients with high blood sugar levels, who will have, according to our findings, worsened prognosis for their disease compared to earlier periods. These considerations provide additional reasons why Governments should place food behaviour policy very high on their health agenda.
